SCHEMBL22609283

SCHEMBL22609283

Cc1onc(C(=O)O)c1Nc1ccc(Cc2ccc(F)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.44
▸ HTT P42858 3/20 0.44
▸ SMN1; SMN2 Q16637 4/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ MEN1 O00255 4/20 0.38
▸ KMT2A Q03164 4/20 0.38
▸ CYP1A2 P05177 2/20 0.38
▸ CYP2C19 P33261 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ P4HTM Q9NXG6 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ LMNA P02545 2/20 0.37
▸ GAA P10253 2/20 0.37
▸ TSHR P16473 1/20 0.37
▸ USP2 O75604 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ APEX1 P27695 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ GFER P55789 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22609257 0.93 ALDH1A1 (0.44) ALDH1A1HTTSMN1; SMN2MEN1KMT2A
SCHEMBL22609213 0.85 ALDH1A1 (0.38) ALDH1A1HTTSMN1; SMN2MEN1KMT2A
SCHEMBL22609253 0.81 ALDH1A1 (0.52) ALDH1A1HTTSMN1; SMN2KMT2AP4HTM
SCHEMBL22609335 0.81 HTT (0.45) ALDH1A1HTTMAPK1MEN1KMT2A
SCHEMBL23486578 0.79 PTGS2 (0.39) ALDH1A1SMN1; SMN2MEN1KMT2ACYP1A2
SCHEMBL23453720 0.79 GRIA1 (0.48) ALDH1A1HTT
SCHEMBL23453731 0.79 RAPGEF4 (0.41) ALDH1A1SMN1; SMN2MAPK1MEN1KMT2A
SCHEMBL22609268 0.75 DHODH (0.43) ALDH1A1HTTSMN1; SMN2MAPTLMNA
SCHEMBL22609248 0.73 ALDH1A1 (0.38) ALDH1A1HTTMAPK1MEN1KMT2A
SCHEMBL23453717 0.72 DHODH (0.41) ALDH1A1CYP2C19CYP2C9ALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF ORFAN BIOTECH SL (ES) 2021-06-10 — — US disclosed
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF ORFAN BIOTECH SL (ES) 2021-06-10 — — US disclosed
EP-3731840-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF Orfan Biotech Inc. (US) 2020-11-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF PNPO, XDH, GLS ALDH1A1 149/4885HTT 4735/4885SMN1; SMN2 4815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback